10-K: Kalaris Therapeutics Reports 2025 Losses, Advances Retinal Drug TH103

Kalaris Therapeutics, a clinical-stage biopharmaceutical company, reported significant net losses in 2025 while advancing its lead product candidate, TH103, for retinal diseases with promising early clinical data.

Summary

• Kalaris Therapeutics, Inc. (formerly AlloVir, Inc.) completed a merger on March 18, 2025, with Legacy Kalaris, becoming a clinical-stage biopharmaceutical company focused on prevalent retinal diseases.
• The company is developing TH103, a novel anti-vascular endothelial growth factor (VEGF) drug engineered for extended intraocular retention and enhanced VEGF inhibition.
• Initial Phase 1a data for TH103 in treatment-naive neovascular Age-related Macular Degeneration (nAMD) patients, announced in December 2025, showed TH103 was generally well tolerated and exhibited improvements in functional and anatomical outcomes at one month post-dosing.
• Key Phase 1a efficacy results included a mean 10-letter improvement in best corrected visual acuity (BCVA), mean 129 µm improvement in central subfield thickness (CST), and approximately 95% reduction in mean intraretinal fluid volume (IRF) at one month.
• Pharmacokinetic analysis from Phase 1a showed dose-adjusted mean Cmax plasma levels of TH103 were 27 to 51-fold lower compared to current leading anti-VEGF agents, consistent with greater intraocular retention.
• Following a single TH103 injection in Phase 1a, 31% of patients required no additional anti-VEGF treatment during the entire six-month follow-up period, suggesting potential for extended durability.
• The company is currently conducting a Phase 1b/2 multiple ascending dose (MAD) study for TH103 in nAMD, with preliminary data expected in the first half of 2027.
• Kalaris Therapeutics reported a net loss of $43.4 million for the year ended December 31, 2025, compared to $69.2 million in 2024, and an accumulated deficit of $160.0 million as of December 31, 2025.
• Cash, cash equivalents, and short-term marketable securities totaled $118.0 million as of December 31, 2025, expected to fund operations into the fourth quarter of 2027.
• The company identified material weaknesses in its internal control over financial reporting as of December 31, 2024, which remained unremediated as of December 31, 2025, and is implementing remediation measures.
• A private placement in December 2025 raised aggregate gross proceeds of $50.0 million through the sale of common stock and pre-funded warrants.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing with mixed sentiment. While the positive early clinical data for TH103 and successful capital raise are encouraging for future development, the significant ongoing financial losses, accumulated deficit, and unremediated material weaknesses in internal controls present notable concerns for investors.

Positives

• TH103 Phase 1a clinical trial showed positive initial data, including a mean 10-letter improvement in BCVA and significant reductions in CST and IRF at one month post-dosing.
• TH103 was generally well tolerated in the Phase 1a trial, with no dose-limiting toxicities or TH103-related serious adverse events observed.
• Pharmacokinetic data suggest greater intraocular retention and reduced systemic exposure for TH103 compared to leading anti-VEGF agents, aligning with its engineered properties.
• A single TH103 injection in Phase 1a resulted in 31% of patients not requiring additional anti-VEGF treatment for six months, indicating potential for extended durability.
• The company successfully raised $50.0 million in gross proceeds from a private placement in December 2025, strengthening its cash position.
• Management expects current cash, cash equivalents, and short-term marketable securities of $118.0 million to fund operations into the fourth quarter of 2027.
• The board and management team possess deep experience in developing and commercializing retina therapeutics, including FDA-approved anti-VEGF therapies.

Negatives

• The company incurred significant net losses of $43.4 million in 2025 and $69.2 million in 2024, with an accumulated deficit of $160.0 million as of December 31, 2025.
• Material weaknesses in internal control over financial reporting were identified as of December 31, 2024, and remained unremediated as of December 31, 2025.
• Cases of transient, mild-moderate intraocular inflammation (IOI) were observed in both Phase 1a and Phase 1b/2 clinical trials, believed to be related to host cell protein impurities, requiring ongoing manufacturing process refinements.
• The company has never generated revenue from product sales and expects to incur significant expenses and operating losses for the foreseeable future.
• The business is heavily dependent on the success of its single lead product candidate, TH103, which is still in early-stage clinical development.
• The company will need substantial additional funding for its continuing operations beyond Q4 2027.

Risks

• Incurring significant losses and expecting to continue to incur significant expenses and operating losses for the foreseeable future, potentially never achieving or maintaining profitability.
• Heavy dependence on the success of TH103, which requires significant clinical testing and may not receive marketing approval or be successfully commercialized, or may experience significant delays.
• Need for substantial additional funding; inability to raise capital when needed or on acceptable terms could force delays, reductions, or elimination of product development programs or commercialization efforts.
• Identified material weaknesses in internal control over financial reporting, with a risk of future identification of additional weaknesses or failure to maintain an effective system, potentially leading to material misstatements.
• Early stage of development efforts; inability to commercialize TH103 or any future product candidate, or significant delays in doing so, would materially harm the business.
• Results of early-stage clinical trials and preclinical studies may not be predictive of future results, and initial success may not be indicative of results in later stage trials.
• Delays or difficulties in patient enrollment for clinical trials could delay or prevent necessary marketing approvals.
• Even if approved, TH103 or other product candidates may fail to achieve sufficient market acceptance by physicians, patients, and third-party payors.
• Reliance on third parties to conduct clinical trials, who may not perform satisfactorily or meet deadlines, potentially delaying or preventing marketing approval or commercialization.
• Complexity of manufacturing biologics, with potential for manufacturing problems (e.g., contamination, raw material shortages, host cell protein issues) leading to delays.
• Inability to obtain and maintain sufficient intellectual property protection, or if the scope of protection is not broad enough, competitors could develop similar products.
• The regulatory approval process is expensive, time-consuming, and uncertain, with no guarantee of timely approval or approval at all.
• The market price of common stock has been and is expected to continue to be volatile.
• Incurring additional costs and increased demands upon management due to complying with laws and regulations affecting public companies.
• Uncertainty regarding the development of an active, liquid, and orderly trading market for common stock, making it difficult for stockholders to sell shares.
• Limitations on transfers of securities utilizing Rule 144 due to prior shell company status.
• Future sales and issuances of common stock or rights to purchase common stock could result in additional dilution and cause the stock price to fall.
• Executive officers, directors, and principal stockholder (Samsara LP) have the ability to control or significantly influence matters submitted to stockholders for approval.
• Controlled company status under Nasdaq rules due to Samsara LP's ownership, allowing reliance on exemptions from certain corporate governance requirements.
• Anti-takeover provisions in charter documents and Delaware law could delay or prevent a change of control.
• Designation of certain courts as the sole and exclusive forum for certain actions could limit stockholders' ability to obtain a favorable judicial forum.
• Changes in tax laws or their interpretation could adversely affect business and financial condition.
• Internal computer systems or those of third parties may fail or suffer security breaches, disrupting product development programs.
• Risk of fraud or other misconduct by employees, contractors, or third parties, leading to significant liability and reputational harm.
• Disruptions at the FDA and other government agencies from funding cuts, personnel losses, regulatory reform, or government shutdowns could hinder timely guidance and approval.

Future Outlook

Kalaris Therapeutics expects to share preliminary data from its ongoing Phase 1b/2 study of TH103 in nAMD in the first half of 2027. Assuming successful completion and favorable results, the company intends to initiate Phase 3 clinical trials for TH103 in nAMD by year-end 2027. The company also plans to expand TH103's development beyond nAMD into other prevalent VEGF-mediated retinal diseases such as diabetic eye disease, retinal vein occlusion (RVO), and potentially retinopathy of prematurity (ROP).

Management Comments

• Management believes the initial data from the Phase 1a clinical trial provides preliminary evidence that TH103 may offer extended treatment durability.
• Management believes continued progress in reducing host cell protein levels in manufactured drug product and corresponding higher total dose amounts administered before IOI is observed reflects continued progress in refining the manufacturing process.
• Management believes specific process modifications may eliminate all remaining host cell protein subtypes to below levels of detection and aims to utilize these modifications in future batches.

Industry Context

StockSavvy.ai notes that Kalaris Therapeutics is entering a highly competitive $15 billion global branded market for anti-VEGF retinal disease treatments, currently dominated by established players like Regeneron (Eylea, Eylea HD), Roche (Lucentis, Vabysmo), and Novartis (Beovu). The company aims to address the significant unmet need for longer-acting anti-VEGF agents, as existing therapies often require frequent clinic visits, leading to patient non-adherence and suboptimal real-world outcomes. The entry of numerous biosimilars for ranibizumab and aflibercept, such as Byooviz, Opuviz, Cimerli, Ahzantive, Enzeevu, and Pavblu, is increasing cost-effectiveness pressure. Kalaris's strategy to develop TH103 with enhanced VEGF inhibition and extended intraocular retention directly targets this durability challenge, positioning it against both established brands and emerging gene therapies from companies like 4D Molecular Therapeutics and RegenexBio, and sustained-release inhibitors from Eyepoint Pharmaceuticals and Ocular Therapeutix.

Comparison to Industry Standards

• TH103 demonstrated 100% inhibition of bovine choroidal endothelial cell (BCEC) proliferation at 1 nanomolar (nM) in preclinical studies, while aflibercept achieved only 80% inhibition even at higher concentrations.
• In a rodent laser-induced CNV model, TH103 showed an approximately two-fold reduction in mean CNV area compared with equimolar concentrations of aflibercept (2.5 µg), and numerically greater reduction than a 10-fold higher concentration of aflibercept (25 µg).
• In a longer-duration mouse experiment (administered 14 days before laser), TH103 showed a significant reduction in mean CNV growth 21 days post-administration, whereas aflibercept showed no reduction compared to control, suggesting superior duration of action.
• TH103 exhibited approximately 780-fold higher affinity for heparan sulfate proteoglycans (HSPG) than aflibercept, which is believed to contribute to its extended intraocular retention.
• Clinical pharmacokinetic analysis showed dose-adjusted mean Cmax plasma levels of TH103 were 27 to 51-fold lower compared to current leading anti-VEGF agents (e.g., aflibercept, ranibizumab), indicating reduced systemic exposure and greater intraocular retention.
• Existing FDA-approved anti-VEGF agents for nAMD include ranibizumab (Lucentis), faricimab (Vabysmo), aflibercept (Eylea, Eylea HD), and brolucizumab (Beovu), with global revenues of approximately $15 billion in 2024. TH103 aims to differentiate by offering longer-lasting therapeutic benefit to reduce treatment burden, a key unmet need not fully addressed by newer agents like Vabysmo or Eylea HD in their registrational trials due to monthly monitoring requirements.

Management Changes

Corporate Governance

Legal Proceedings

• Two complaints filed by purported AlloVir stockholders (Keller v. AlloVir, Inc. et al., Morgan v. AlloVir, Inc. et al.) alleging misrepresentation/omission in the proxy statement/prospectus related to the merger, seeking to enjoin or rescind the merger and damages. The company denies the allegations.
• A securities class action lawsuit (Zerbato v. AlloVir, Inc. et al.) filed against AlloVir and two officers, alleging false and misleading statements regarding AlloVir's Phase 3 studies of posoleucel. This lawsuit was resolved for $1.0 million, with final approval of settlement and dismissal with prejudice on July 30, 2025.
• A derivative lawsuit (Lister v. Brainard et al.) filed against certain AlloVir officers and directors, alleging violations of Section 14(a) of the Exchange Act, breach of fiduciary duties, unjust enrichment, waste of corporate assets, gross mismanagement, and abuse of control. This lawsuit was voluntarily dismissed without prejudice on August 1, 2025.

Related Party Transactions

• Samsara BioCapital L.P. (Samsara) is the company's majority stockholder, beneficially owning approximately 56.5% of outstanding common stock as of December 31, 2025.
• Samsara has provided significant equity and debt financing to Legacy Kalaris since its inception.
• Samsara provides management and operational support services under a Business Services Agreement (BSA), for which the company recognized $0.3 million in general and administrative expenses in 2025 and $0.2 million in 2024.
• The company entered into a Royalty Agreement with Samsara in July 2024, redeeming 10,080 shares of common stock in exchange for a low single-digit tiered royalty on future net sales of products developed using UCSD-licensed technology. A long-term liability of $32.1 million was recorded for this obligation.
• The company issued convertible promissory notes to Samsara and other investors in 2024 and 2025, which were converted or cancelled in connection with the merger.
• Members of the company's management and board of directors received $0.1 million in consulting fees from related parties for each of the years ended December 31, 2025 and 2024.

Stakeholder Impact

• Shareholders: Potential for dilution from future capital raises, stock price volatility, and limited influence due to anti-takeover provisions and Samsara LP's controlled company status. The resolution of the securities class action for $1.0 million and dismissal of the derivative lawsuit reduce immediate legal overhang.
• Employees: The company's future success depends on retaining key executives and scientists, and attracting qualified personnel. Stock-based compensation plans are in place to incentivize employees. Management changes have occurred to strengthen the team.
• Patients: Potential for a new, longer-lasting treatment option (TH103) for prevalent retinal diseases like nAMD, DME, DR, and RVO, addressing the high treatment burden of existing therapies. However, observed IOI cases in trials highlight safety considerations that require ongoing manufacturing refinements.
• Creditors: The company's significant accumulated deficit and ongoing losses indicate a reliance on future financing to meet obligations, though current cash is projected to fund operations into Q4 2027.
• Suppliers/Contract Manufacturers: Continued reliance on third-party CDMOs and CROs for manufacturing and clinical trials, with risks of supply disruptions or performance failures impacting development timelines.

Next Steps

• Share preliminary data from the ongoing Phase 1b/2 study of TH103 in nAMD in the first half of 2027.
• Initiate Phase 3 clinical trials of TH103 for nAMD by year-end 2027, assuming successful completion of Phase 1b/2 and favorable regulatory discussions.
• Expand the development of TH103 beyond nAMD into other prevalent VEGF-mediated retinal diseases such as diabetic eye disease, retinal vein occlusion (RVO), and potentially retinopathy of prematurity (ROP).
• Commercialize TH103, if approved, with its own specialty salesforce and potentially expand into other ophthalmic therapeutics.
• Strengthen the development pipeline through internal discovery, in-licensing, strategic collaborations, and/or acquisitions.
• Continue to advance additional process refinements in manufacturing to further reduce host cell protein levels in drug product, with new material expected in Q2 2026.
• Continue to implement additional measures and risk assessment procedures to remediate identified material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

Kalaris Therapeutics presents a high-risk, high-reward profile. The positive early clinical data for TH103, particularly its potential for extended durability and reduced systemic exposure compared to market leaders, is a strong positive signal in a large and underserved market. The recent capital raise provides a runway into Q4 2027. However, the company's significant accumulated losses, ongoing cash burn, and identified material weaknesses in internal controls introduce substantial financial risk. The early stage of TH103's development means considerable uncertainty remains regarding its ultimate success, regulatory approval, and commercial viability. Given the promising but preliminary clinical results and the significant operational and financial challenges, a 'hold' recommendation is appropriate for investors who are comfortable with high risk and are awaiting further de-risking through later-stage clinical trials and remediation of internal control issues.

Keywords

Kalaris Therapeutics, TH103, Retinal Diseases, nAMD, VEGF inhibitor, Biopharmaceutical, Clinical Stage, Phase 1a, Phase 1b/2, Clinical Trials, SEC Filing, 10-K, Drug Development, Ophthalmology, Macular Degeneration, Biologics, Samsara BioCapital, Merger, Capital Raise, Internal Controls, Intellectual Property